Next Phase of CBD Study Launched by Strainprint Technologies and Gynica

Strainprint Technologies, Ltd. is a Toronto, Canada-based company that focuses on CBD analytics and data. The company utilizes longitudinal and observational data sets to promote a scientific understanding of CBD as a mainstream therapy. As for Gynica, it is an Israeli research group that provides proven CBD-based solutions for women and their health.

Strainprint Technologies issued a press release announcing that the two are launching the next stage of a clinical trial geared toward the development of a product to treat endometriosis and associated symptoms. The phase will survey Canadian and Israeli woman suffering from endometriosis through a comprehensive questionnaire. The survey will also address how they use CBD to treat their symptoms.

Strainprint and Gynica partnered in 2018 and conducted a preliminary clinical study concerning endometriosis and CBD. This new phase will utilize Strainprint’s database of patient reported outcomes.

Gynica Professor Moshe Hod, who is also the President of the European Association of Perinatal Medicine and Professor of Obstetrics and Gynecology at Tel Aviv University Medical School, shared in the press release,

“180 million people worldwide experience severe pain daily as a result of tissue similar to the uterine lining migrating to other organs inside the body, causing debilitating pain, infertility, fatigue, gastrointestinal and/or bladder symptoms.” He continued. “Our objective is to recruit suffering candidates to explore cannabis as a viable therapy in the hopes of developing improved diagnostics and treatments to those who are undertreated by current solutions.”

Michelle Arbus, Strainprint's VP of Research also shared in the press release,

“We believe many women will be eager to take part in this ground-breaking research.”

She continued.

“Our online Strainprint Community already provides a safe space to discuss endometriosis and cannabis treatment with fellow sufferers, and through this questionnaire, participants will have the opportunity to contribute to research and play a more active role in their healthcare with alternative methods not yet explored. Some of these endometriosis sufferers have dealt with excruciating pain for many years and do not tolerate or respond to the current treatment options available. They will now have a chance to be pioneers in a study that could make medical history by helping others not only manage their symptoms, but also greatly improve their quality of life.”

In the United States, research on marijuana is hampered by federal marijuana prohibition. Marijuana is illegal under federal law and is classified as a Schedule I substance.

All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.